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Liquid chromatography–mass spectrometry (LC–MS) with generic gradient elution for a large 
number of chemically different compounds is a common approach in drug development, 
used to acquire a large amount of data in a short time frame for drug candidates. The analysis 
with non-optimized parameters however may lead to a poor method performance for many 
compounds, and contains a risk of losing important information. Here, generic electrospray time 
of flight (ESI-TOF) MS methods in various pH conditions were tested for 55 chemically diverse 
compounds (10 acids, 25 bases, 17 neutrals, and 3 amphoterics), aiming to find best analytical 
conditions for each compound, for studies of in vitro metabolic properties in liver preparations. 
The effect of eluent pH and elution gradient strength on chromatographic performance and 
electrospray MS ionization efficiency were examined for each compound.  The data are evaluated 
how well the best generic approach could cover the analysis of test compounds and how many 
compounds would still need completely different analytical conditions after that. Aqueous 
mobile phase consisting of 0.05% acetic acid and 5 mM ammonium acetate (pH 4.4) showed 
the best general suitability for the analyses, showing adequate performance for metabolite 
profiling for 41 out of 55 compounds either in positive or negative ion mode. In positive ion 
mode, the main limitation of performance in various pH conditions was generally not the lack 
of ionization, but rather the poor chromatographic performance (inadequate retention or poor 
peak shape), suggesting that more emphasis should be put in finding conditions providing best 
chromatographic performance, rather than highest ionization properties. However, a single 
generic approach for a large number of different compounds is not likely to produce good 
results for all compounds. Preferably, at least two or three different conditions are needed for 
the coverage of a larger number of structurally diverse compounds.
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analysis would lead to highest general applicability, even though 
it is very well known that with LC–ESI–MS acidic compounds 
are usually negatively ionized (deprotonated) in basic conditions 
and basic compounds are on the contrary positively ionized (pro-
tonated) in acidic conditions (Kostiainen and Kauppila, 2009). 
The electrospray ionization process in LC–MS is however a very 
complex phenomenon having multiple affecting factors, such as 
volatility, viscosity, surface tension, conductivity, ion strength, and 
pH of the used solvents and additives in LC mobile phase, and 
depending on the properties of analyte compounds and mobile 
phase constituents, sometimes better ionization may occur in the 
conditions clearly against these rules (Kostiainen and Kauppila, 
2009). In addition, the chromatographically co-eluting matrix 
components may suppress or enhance the ionization process 
(Mallet et al., 2004; Cappiello et al., 2008). Therefore, mobile 
phase constituents have very high and sometimes unpredictable 
effect to the ESI response of the analytes, and solvents and addi-
tives used must be carefully chosen and tested to obtain high-
quality data from analyses.
IntroductIon
Liquid chromatography–mass spectrometry (LC–MS) techniques 
employed in drug metabolism studies of early drug discovery very 
often utilize the so called generic gradient elution, i.e. only structure 
group-optimized or even totally non-optimized eluent pH and gra-
dient strength are used for all analytes (Lee and Kerns, 1999; Cheng 
et al., 2001; Hop et al., 2002; Kostiainen et al., 2003; Castro-Perez 
et al., 2005: Kamel and Prakash, 2006; Pedraglio et al., 2007). This 
provides high throughput and fast turn-around time, and is usu-
ally considered as the approach giving the highest amount of data 
with the lowest time consumption. The use of non-optimized test 
conditions however may lead to sacrificed data quality for many 
compounds, producing biased results, often in a form of false nega-
tives in metabolite screening.
Despite their common use in industry, performance and data 
quality obtained with such methods are however rarely stud-
ied, at least in format of published data with a high number of 
compounds with diverse chemical nature. Also not much atten-
tion is paid to what kind of eluent conditions in case of LC–MS Frontiers in Pharmacology  |  Drug Metabolism and Transport    August 2010  | Volume 1  | Article 10  |  2
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Chromatographically  valid  data  of  gradient  pH  conditions 
  considering the generic elution gradients with a very high number 
of compounds is described in the literature by Law (2004), result-
ing in a conclusion that gradient elution at neutral pH conditions 
is highly successful for most compounds, as long as logD values 
of the analytes are > –2. If the pH is increased above 8, the chro-
matographic  performance  for  acidic  compounds  is  weakened, 
whereas the pH below 4 decreases the performance with basic 
compounds. This study did not examine the effect of pH from the 
mass spectrometric point of view. Despite the chromatographic 
performance, most of the generic gradient conditions for drugs or 
drug-like compounds are at pH conditions 3–4 or even below, as 
in most cases with LC–MS utilizing electrospray ionization (ESI) 
the protonation (and thus detection sensitivity) is favored at this 
pH, especially with basic compounds.
Some papers focusing on development of generic gradients for 
LC–MS have been published, describing however the use of only 
minor groups of compounds (2–13 compounds), and thus not 
showing the real applicability of the methods for compounds of 
higher chemical diversity (Ayrton et al., 1998; Chu et al., 2002; Seto 
et al., 2002; Mensch et al., 2007). Ayrton et al. (1998) described the 
development of generic HPLC–UV gradient elution conditions for 
11 compounds, but tested the method only for two compounds with 
mass spectrometric detection. Seto et al. (2002) in turn described 
a generic gradient LC–MS method with ion pairing reagents, con-
sidering the use of various mobile phase additives, but focusing 
on analysis of only four acidic compounds. Chu et al. (2002) built 
up a generic LC–MS–MS method for in vitro blood–brain barrier 
test assay; showing its applicability with 28 new chemical entities 
(NCE). They however applied both positive and negative mode 
ionization polarities with both ESI and APCI ionization modes; 
and three different chromatographic columns for compounds with 
different retention behavior, so that the methods used in the end 
were really not so “generic”. Also Mensch et al. (2007) described a 
generic UPLC–MS–MS method for analysis of NCEs in drug dis-
covery phase permeability studies, but only six model compounds 
were used in evaluating the performance of the method. The effect 
of eluent pH on chromatographic and mass spectrometric per-
formance in generic gradient elution was most comprehensively 
studied by Delatour, who concluded that with their 11 basic drugs 
the basic pH provided clearly better chromatography in comparison 
to acidic conditions, without significant decrease in positive ion 
mode ESI–MS detection (Delatour and Leclercq, 2005).
Our actual goal was to develop LC–ESI–MS methods to be used 
in in vitro metabolism studies of 55 chemically diverse compounds 
in rat and human liver microsome and homogenate incubations, 
monitoring both substrate depletion and metabolite formation 
at the same time. The compounds were selected from the list of 
validation substances of European Centre for the Validation of 
Alternative Methods (ECVAM), and they have been used to study 
the comparison of metabolic properties in rat and human liver 
homogenate and microsomal incubations in vitro. The ECVAM list 
of validation compounds is not based on chemical classes (acids, 
bases, neutrals, amphoterics) but rather on the different toxicities of 
the compounds. For this reason the final set contained a relatively 
high number of chemically neutral compounds, so that this class of 
compounds was present in a clearly higher proportion than neutral 
compounds in drug discovery in general (Law, 2004). However, as 
the multiresidual techniques are nowadays of high importance in 
several analytical fields, such as metabolism, environmental and 
forensic sciences, or plant and human metabolomics, the search 
of compromise between optimal conditions for chromatographic 
separation, and detection is of great interest also in the application 
areas other than drug metabolism studies.
The methods for each compound were developed with one 
generic method as a starting point, and testing the effect of eluent 
pH on both chromatographic performance and mass spectrometric 
ionization efficiency (detection sensitivity). The data acquired dur-
ing this stage was combined and analyzed here for assessing whether 
certain conditions would show the best general applicability in this 
type of studies, and thus evaluating the performance of the most 
typical gradient elution conditions for LC–ESI–MS used in drug 
discovery studies. It is worth stressing that our aim was not to 
develop one set of LC–MS conditions that would enable analysis of 
samples from all 55 test compounds; therefore the pH and the ion 
strengths of the LC effluents were not optimized more than by using 
six of the most typically used LC–MS aqueous mobile phases.
MaterIals and Methods
cheMIcals
All chemicals and solvents were HPLC grade and were purchased 
from VWR International Ltd (Espoo, Finland). LichroSolv ace-
tonitrile was from Merck KGaA (Darmstadt, Germany), while 
formic acid, acetic acid, ammonium formate, ammonium acetate, 
and ammonia were from BDH Laboratories Ltd (Poole, England). 
Laboratory water was prepared with Direct-Q (Millipore S.A., 
Molsheim, France) water purification system and was UP grade 
(ultrapure, 18.2 MΩ).
saMple preparatIon
The test samples were prepared to provide similar injection condi-
tions with real incubation samples. Thus, samples were prepared 
to 0.5 μM concentration in 50% acetonitrile in 150 mM phosphate 
buffer, so that this corresponds to 1 μM incubation (4% of the 
initial substrate concentration of 25 μM to be used in the following 
metabolism studies) where enzymatic reactions are quenched with 
an equal volume of acetonitrile.
lIquId chroMatography Mass spectroMetry
A Waters Alliance 2695 high performance liquid chromatographic 
system (Waters Corp., Milford, MA, USA) with an autosampler, a 
column oven, and a vacuum degasser was used with Waters XBridge 
Shield RP18 column and Phenomenex Luna C18 (2 × 4 mm) pre-
column. In some cases also Waters XBridge C18 or Phenomenex 
Luna-C18 columns were used if poor peak shape was observed 
with the first tested column. All columns used had 2.0–2.1 × 50 
mm dimensions and 3–3.5 μm particle sizes. The column selec-
tion was based on stationary phases able to cover wide pH range 
(XBridge C18 pH 1–12, XBridgeShieldRP pH 2–11, Luna 1.5–10) 
and authors’ good experiences about the columns over several years 
in various chromatographic conditions. Temperature of column 
oven was 30°C and injection volumes used were 10 μl. The data was 
acquired with a Micromass LCT time of flight (TOF) mass spec-
trometer (Micromass Ltd., Manchester, England) equipped with www.frontiersin.org  August 2010  | Volume 1  | Article 10  |  3
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a LockSpray electrospray ionization source, used both in positive 
and negative ion polarity. Cone voltages between 16 and 28 V were 
used (roughly optimized for each compound). Capillary voltages 
of 3.5 and 2.8 kV were used at positive and negative ion mode, 
respectively. Nitrogen was used as a nebulizer and drying gas with 
flow rates of 100 and 800 l/h, respectively. The source and desolva-
tion temperatures used were 150 and 350°C, respectively. Leucine 
encephalin ([M+H]+ m/z 556.2771) and raffinose ([M–H]– m/z 
503.1612) were used as lock mass compounds in accurate mass 
measurement with positive and negative ion modes, respectively, 
and were delivered into LockSpray probe with syringe pump to 
obtain about 160 counts/s. The mass spectrometer and HPLC sys-
tem were operated under MassLynx 4.0 software.
chroMatographIc condItIons and Method developMent
In method development phase the study compounds were divided 
to batches of 3–10 compounds, based on their chemical structures 
or acid/base properties, and LC–MS conditions for each compound 
were briefly optimized by acquiring test data for all compounds in a 
single batch at the same time. As a first run conditions a gradient elu-
tion with 2%–2%–60%–90%–90% acetonitrile in 0–1–3–5–6 min 
was applied for each compound (in batches of 3–10 compounds), 
followed by column equilibration. After this, few runs for optimiz-
ing gradient strength (slope of the organic phase proportion) were 
acquired, followed by runs with various aqueous phase pH condi-
tions and different MS ionization polarities. In all cases, gradient 
elution was used (no isocratic runs). Acetonitrile was chosen as 
organic eluent phase over methanol, as it usually provides better 
chromatographic peak shapes. The eluent flow rate used was 0.4 ml/
min. The aqueous eluent phases used were 0.1% formic acid (FA, 
pH 2.8), 0.1% acetic acid (AA, pH 3.2), 0.05% acetic acid +5 mM 
ammonium acetate (pH 4.4), 2 mM ammonium formate (NH4OF, 
pH 6.0), 2 mM ammonium acetate (NH4OAc, pH 6.7), and 10 mM 
ammonia (NH4OH, pH 9.8). After this the acquired data was used to 
extract the optimum LC–MS conditions for each single compound; 
and these methods were used later in in vitro metabolism studies 
(data to be reported elsewhere). For compounds with poor peak 
shape, also the effect of different columns (see above) were tested 
for improving chromatographic peak shapes.
results and dIscussIon
suItabIlIty of generIc gradIent condItIons for the test  
set coMpounds
The suitability of the tested HPLC eluent conditions for each 55 
test compounds are shown in Table 1. Mass spectrometric ioniza-
tion efficiencies were rated for each compound with symbols to 
mark detection sensitivity (a) high enough for monitoring formed 
metabolites “++”, (b) good enough to monitor substrate depletion 
but not the formed metabolites “+”, or (c) poor sensitivity being 
not enough even to monitor substrate depletion “−”. The sensitivity 
limit for monitoring metabolites (metabolite profiling) was con-
sidered as signal-to-noise ratio >10 from 1% concentration of the 
actual initial incubation concentration (25 μM), whereas the limit 
for monitoring substrate depletion was considered as a detected 
signal (S/N > 3) from test sample having 4% concentration of the 
actual initial incubation concentration. When chromatographic 
problems were observed, in form of poor peak shape or inadequate 
retention behavior (to separate parent and metabolites) preventing 
the use of certain eluent conditions for metabolite profiling despite 
of good ionization, the abovementioned symbol was marked within 
parentheses “(++)”. Poor peak shape was specified as asymmetric 
factor A/B < 0.4 (tailing peak) or A/B > 2 (fronting peak), where 
A = peak width before the peak top and B = peak width after the 
peak top (both measured from 5% peak height). As the chroma-
tographic separation or peak shape are not so crucial in analysis of 
metabolic stability, this chromatographic criteria was not applied 
to “+” − symbols. The criterion for adequate retention was set so 
that normalized retention time (retention time minus dead time) 
should be at least ten times the peak width (measured from 5% peak 
height). In addition, the number of each symbol for each HPLC 
conditions in Table 1 is summarized to Table 2. In addition, the best 
conditions for each compound were marked with a “*” symbol.
As already mentioned above, the test compound set was not 
selected primarily for the analytical considerations discussed in the 
present study, but rather focused to obtain a suitable test set for 
metabolism studies. For this reason the number of neutral com-
pounds is relatively high with respect to other classes, whereas only 
few amphoteric compounds are included. Even if the 55 compounds 
offer structurally quite a diverse selection of compounds, the number 
is still not very high, as some metabolomics studies may describe 
methods monitoring several hundreds of compounds at the same 
time. However, metabolomics studies do not provide similar approach 
for the assessment of analytical conditions as followed here.
Generally, and not surprisingly, the results showed clearly that 
none of the six eluent pH conditions was able to provide adequate 
analytical conditions to cover successful metabolite profiling, or 
even monitoring the substrate depletion, for all the 55 test com-
pounds. However, suitable conditions for monitoring at least the 
substrate disappearance were found for all of the 55 test com-
pounds. As expected, the positive ion mode electrospray ionization 
covered a higher number of test compounds in all conditions, even 
when working with ammonia in clearly basic conditions at pH 9.8. 
However, this latter result is somewhat biased by a high number 
of basic compounds in test group (bases 25/55, acids 10/55). The 
results are collected to Table 1. It is obvious that negative ion mode 
was superior in ionization efficiency with acidic compounds in 
all  tested  pH  conditions,  whereas  the  basic  compounds  were 
self-evidently ionized better with positive ion mode. The neutral 
compounds were generally ionized with positive ion mode, and 
suitability of negative ion mode increased with increasing pH.
Of the six tested eluent conditions, the one with 0.05% acetic 
acid and 5 mM ammonium acetate (pH 4.4) showed the highest 
suitability for the test compounds, as 41 of the 55 compounds 
showed LC–MS performance filling the criteria set as adequate 
for metabolite profiling, either with positive or negative ion mode, 
when using this eluent. More specifically, 31 of the test compounds 
worked well in positive ion mode and 17 in negative ion mode 
(Table 2). The actual strength of these conditions seemed to be a 
good chromatographic performance for most of the compounds, 
as only three compounds showed inadequate chromatographic 
retention behavior or poor peak shape. However, 13 of the test 
compounds showed completely inadequate performance even for 
monitoring substrate depletion in these conditions due to poor 
detection sensitivity. Also, even though the mobile phase with Frontiers in Pharmacology  |  Drug Metabolism and Transport    August 2010  | Volume 1  | Article 10  |  4
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When using 2 mM ammonium acetate and 10 mM ammonia as an 
aqueous eluent phase, the corresponding numbers of compounds 
with good ionization but poor chromatography were 18 and 17, 
respectively. In this context there was a striking difference between 
these three aqueous mobile phases and the mixture containing 
0.05% acetic acid and 5 mM ammonium acetate (pH 4.4) provid-
ing clearly better chromatographic performance for a large set of 
compounds. This effect was most distinct for basic compounds, 
as peak shapes for acidic and neutral compounds were generally 
clearly better. An example of the pH/mobile phase additive effect 
for peak shapes is shown in Figure 1, where propranolol has very 
poor tailing peaks when ammonium formate, ammonium acetate 
and ammonia are used in aqueous mobile phase (traces C, E, and 
F), but on the contrary very good chromatographic performance 
when formic acid, acetic acid or mixture of ammonium acetate and 
acetic acid are used (traces A, B, and D). The ion strengths of the 
buffers were intentionally kept rather low to provide a good ESI–MS 
ionization efficiency, which may in some cases be the reason for 
the observed poor chromatographic peak shapes. Thus, from the 
chromatographical point of view higher buffer ion strength would 
improve the quality of the data for certain compounds, but this 
would also lead to clearly lower ionization response and thus poorer 
detection sensitivity.
The injection conditions may have their effect to the poor peak 
shapes in some cases. The acetonitrile content (50%) in injection 
solvent has clearly increased elution strength with respect to the 
initial gradient conditions (2%), causing some fronting in the peak 
shape if too high injection volumes are used. This phenomenon 
is clearly more pronounced with analytes that have low retention, 
which again in turn increases the importance of good chromato-
graphic retention behavior. We however deliberately did not change 
the injection solvent, as in in vitro metabolism studies the samples 
usually contain high content of organic solvent used for quenching 
the enzymatic reactions in the incubations, and in high throughput 
analyses it is often a waste of time to evaporate the organic solvent 
or dilute the sample with aqueous solvent. Moreover, also in the 
high throughput in vivo plasma or serum analyses the samples are 
often prepared with protein precipitation with acetonitrile, using 
ratios 2:1–4:1 between solvent and sample, leading to even stronger 
injection solvents than used here.
The column chemistries (particle surface modification) have 
slight effect to the observed results. As stated above, our column 
selection was based on need for wide range pH tolerance for the 
columns, and good experiences with the used column chemistries 
in various demanding analyses. It may however be the case that 
0.05% acetic acid and 5 mM ammonium acetate showed the best 
general suitability for the test compounds, it was the best aqueous 
mobile phase only for 17 of the compounds. This again shows that 
even though this mobile phase is generally highly useful, it still leads 
to a less than-optimal performance for most of the compounds.
The second highest suitability was obtained with 0.1% acetic 
acid (pH 3.2) as an aqueous mobile phase, as for 35 out of 55 
compounds the criteria set for monitoring both substrate depletion 
and the forming metabolites were fulfilled either with positive or 
negative ion mode. More specifically, 25 of the compounds filled 
the criteria in positive ion mode ionization, and 13 in negative ion 
mode ionization. The chromatographic performance was found 
unsuitable for seven compounds. The 0.1% acetic acid as an aque-
ous mobile phase provided the best performance for ten of the 
55 compounds.
In terms of the number of compounds fulfilling the set criteria 
for metabolite profiling, either with positive or negative ion mode 
electrospray ionization, the suitability of 0.1% formic acid (pH 2.8), 
2 mM ammonium formate (pH 6.0) and 10 mM ammonia (pH 
9.8) were generally about equal, all leading to an adequate perform-
ance for 25–29 compounds. Clear differences between these three 
mobile phases were however apparent: 2 mM ammonium formate 
was the best aqueous mobile phase for 22 of the compounds, while 
ammonia was the most suitable only for five of the compounds, and 
formic acid was not the best for any of the 55 compounds. This latter 
issue is worth stressing, as though several mobile phase conditions 
gave performance that fulfilled the criteria set for metabolite profil-
ing (marked “**”), large, even over 10-fold, sensitivity differences 
were observed between them in some cases. The 2 mM ammonium 
acetate was suggested to have clearly the lowest general suitability 
for the analysis of the used test compounds, as the metabolite pro-
filing criteria were fulfilled only with 18 of the 55 compounds. The 
relatively poor performance with ammonium acetate and formic 
acid as mobile phase additives is somewhat unexpected and worth 
noticing, as these both are commonly used in LC–ESI–MS.
With 2 mM ammonium formate, 2 mM ammonium acetate, 
and 10 mM ammonia as an aqueous mobile phase, it was clearly 
observed that most of the detected problems were introduced by 
inadequate  chromatographic  performance  (poor  peak  shape), 
not by the mass spectrometric ionization properties. The Table 2 
shows that when using 2 mM ammonium formate as an aqueous 
mobile phase, there were 24 compounds for which positive ion 
mode ESI ionization response high enough for metabolite pro-
filing was observed, but at the same time their chromatographic 
properties were very poor and non-suitable for the intended study. 
Table 2 | Number of different symbols in Table 1 in the tested LC–ESI–TOF–MS mobile phase conditions.
  0.1% FA  0.1% AA  2 mM NH4OF  5 mM NH4OAc   2 mM NH4OAc  10 mM NH4OH 
       +0.05% AA
  ESI+  ESI−  ESI+  ESI−  ESI+  ESI−  ESI+  ESI−  ESI+  ESI−  ESI+  ESI−
++   25  5  25  13  19  16  32  17  11  14  19  12
+  8  8  8  4  4  0  7  3  4  2  5  4
(++)  4  1  4  0  24  1  3  0  18  0  17  2
−  18  41  18  38  8  38  13  35  22  39  14  37www.frontiersin.org  August 2010  | Volume 1  | Article 10  |  7
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of metabolic stability), the incubation concentrations should reflect 
more truthfully the concentrations observed in circulation in vivo, 
i.e. around 1 μM. With these kinds of parent compound levels even 
the modern instruments need again optimal conditions in order 
to provide high-quality data for metabolism studies.
acIds
The  test  group  contained  10  compounds  classified  as  acids. 
Obviously, the negative ion mode ESI was clearly more sensitive 
for almost all of them in all tested pH conditions, only exceptions 
being observed with acetaminophen, cycloheximide, and warfa-
rin. Observed sensitivity was adequate for metabolite profiling in 
negative ion mode for all other acidic compounds except aceta-
minophen when aqueous phase used was 0.1% acetic acid (pH 
3.2), 2 mM ammonium formate (pH 6.0), or mixture of 0.05% 
acetic acid and 5 mM ammonium acetate (pH 4.4). Naturally, the 
some columns with narrower pH range (traditionally pH 2–7) 
might have produced better chromatographic behavior for certain 
compounds, but then again those could not have been used in all 
tested pH conditions. Also, the use of even higher pH (>12) than the 
highest pH used here could have provided better chromatographic 
performance for strong bases, but this again would have led to poor 
applicability with most columns available.
Considering that the mass spectrometer used is from the begin-
ning of the decade, and taking into account the dramatic increase 
in detection sensitivity with the recent TOF instruments, it is also 
clear that if such high study compound concentrations are used in 
metabolism studies as described in this paper, the new instruments 
are capable for detection sensitivity adequate for metabolite profil-
ing even in slightly misoptimized analytical conditions. However, 
to obtain more meaningful results, especially regarding the parent 
compound disappearance (substrate depletion for the estimation 
FIgurE 1 | Positive ion mode LC–ESI–TOF–MS ion chromatograms for propranolol at various mobile phase pH conditions. (A) 0.1% formic acid (pH 2.8); 
(B) 0.1% acetic acid (pH 3.2); (C) 2 mM ammonium formate (pH 6.0); (D) 0.05% acetic acid with 5 mM ammonium acetate (pH 4.4); (E) 2 mM ammonium acetate 
(pH 6.7); (F) 10 mM ammonia (pH 9.8).Frontiers in Pharmacology  |  Drug Metabolism and Transport    August 2010  | Volume 1  | Article 10  |  8
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acidic pH provided also good chromatographic peak shape and 
retention behavior for these compounds. When eluent pH was <3 
or >7, the ionization efficiency started to decrease for some of the 
acids. Also as expected, the neutral or basic conditions (pH ≥ 7) 
led  to  inadequate  chromatographic  retention  for  some  of  the 
acidic compounds.
Acetaminophen was only poorly ionized in negative ion mode, as 
the sensitivity was adequate only for monitoring metabolic stability, 
probably because the acidity of acetaminophen is due to a phenol 
group that is only a weak acid. The positive ion mode ionization 
was not very good for acetaminophen in any pH conditions either. 
For cycloheximide and warfarin, good ionization efficiency in posi-
tive ion mode electrospray was observed when 2 mM ammonium 
formate or 10 mM ammonia was used as aqueous mobile phase 
even though the imide functionality in the compounds would 
  suggest acidic behavior. Warfarin also showed different behavior 
in comparison with other acids, as it was very well ionized in both 
positive and negative ion mode, being therefore easy to analyze by 
LC–ESI–MS in practically all conditions. The ion chromatograms 
of warfarin are shown in Figure 2. An opposite example of chroma-
tographic performance of acidic compounds is shown in Figure 3, 
where large differences in negative ion mode ionization efficiency 
for ibuprofen are observed as a function of pH.
Aminoglutethimide, aminopterin, and nalidixic acid were clas-
sified as amphoterics rather than acids, in spite of the presence of 
acidic imide functionality in aminoglutethimide and carboxylic 
acid functionality in aminopterin and nalidixic acid. In addition 
to acidic functionalities, aminoglutethimide contains also basic 
FIgurE 2 | Positive and negative ion mode LC–ESI–TOF–MS ion 
chromatograms for warfarin at various mobile phase pH conditions. 
(A) 0.1% formic acid (pH 2.8); (B) 0.1% acetic acid (pH 3.2); (C) 2 mM 
ammonium formate (pH 6.0); (D) 0.05% acetic acid with 5 mM ammonium 
acetate (pH 4.4); (E) 2 mM ammonium acetate (pH 6.7); (F) 10 mM ammonia 
(pH 9.8). Ionization polarities are shown in each trace.www.frontiersin.org  August 2010  | Volume 1  | Article 10  |  9
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aniline moiety, whereas aminopterin contains primary amines 
and aromatic imines, and nalidixic acid contains tertiary amine 
and aromatic imine functionalities. These basic functionalities also 
show their effect in observed results, as all of these three com-
pounds were ionized clearly better in positive than in negative ion 
mode electrospray. With aminopterin also good negative ion mode 
ionization efficiency was observed in most of the acidic condi-
tions tested. Due to the ionization of the mentioned functionalities, 
also some chromatographic peak shape and retention problems 
were observed in acidic and as well as in basic conditions, while 
the mixture of 0.05% acetic acid and 5 mM ammonium acetate 
(pH 4.4) showed clearly the best performance with these three 
compounds. Positive ion mode chromatograms of nalidixic acid 
are as an example in Figure 4, showing very good peak shapes 
and retention when formic acid, acetic acid or mixture of acetic 
acid and ammonium acetate are used in mobile phase (traces A, 
B, and D), but poor peak shape when ammonium formate and 
  ammonium acetate (without acetic acid) are used (traces C and 
E), and poor peak shape and decreased retention when ammonia 
is used in mobile phase (trace F).
bases
Based on the amine functionalities in the compounds, 25 of 
them were classified as bases. As expected, a clear majority of 
them  showed  ionization  efficiency  adequate  for  metabolite 
profiling in positive ion mode practically in all tested pH con-
ditions. However, when using basic pH conditions or ammo-
nium acetate or ammonium formate in eluents, surprisingly 
high number of chromatographic peak shape problems were 
observed. In high pH these are mostly explained by interactions 
between basic functionalities and free silanol groups remaining 
in the column, even though the columns used were   manufactured 
FIgurE 3 | Negative ion mode LC–ESI–TOF–MS ion chromatograms for ibuprofen at various mobile phase pH conditions. (A) 0.1% formic acid (pH 2.8); 
(B) 0.1% acetic acid (pH 3.2); (C) 2 mM ammonium formate (pH 6.0); (D) 0.05% acetic acid with 5 mM ammonium acetate (pH 4.4); (E) 2 mM ammonium acetate 
(pH 6.7); (F) 10 mM ammonia (pH 9.8).Frontiers in Pharmacology  |  Drug Metabolism and Transport    August 2010  | Volume 1  | Article 10  |  10
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with   ethylene-bridged silica, resulting in low number of non-
end-capped silanols. As with acidic compounds, the generally 
best  chromatographic  performance  was  thus  obtained  when 
using low pH eluents, especially with the mixture of 0.05% ace-
tic acid and 5 mM ammonium acetate (pH 4.4). The peak shape 
problem (good ionization but poor peak shape) is described in 
Figure 1 with propranolol, whereas example concerning reten-
tion behavior problems is shown in Figure 5 with nicotine. For 
nicotine, a satisfactory peak shape but clearly inadequate reten-
tion is observed when formic acid, acetic acid, or mixture of acetic 
acid and ammonium acetate are used in mobile phase (traces A, 
B, and D). Increased retention but extremely poor peak shape 
is obtained when using ammonium formate in mobile phase, 
whereas with ammonium acetate the ionization is suppressed 
below detection limit. However, when using 10 mM ammonia 
in mobile phase, an excellent peak shape and good ionization 
efficiency in positive ion mode are obtained.
In the negative ion mode ionization, a detection sensitivity 
  adequate even for monitoring the parent compound disappearance 
was rarely obtained for bases, the exception being haloperidol, for 
which good ionization efficiency was obtained especially with the 
mixture of 0.05% acetic acid and 5 mM ammonium acetate.
neutrals
The remaining 17 compounds lacking clearly basic or acidic func-
tional groups, or having no change in calculated logD value over 
pH range 2–11, were classified as neutrals. Their behavior with 
respect to ionization efficiency in positive or negative ion mode 
was generally not so clearly divided, as some showed better ioniza-
tion in positive and others in negative ion mode. The compounds 
with better positive ion mode ionization were however in majority 
over those with more efficient negative ion mode ionization. The 
slightly acidic 2 mM ammonium formate was observed to be the 
most suitable of the tested mobile phase conditions for this group 
FIgurE 4 | Positive ion mode LC–ESI–TOF–MS ion chromatograms for nalidixic acid at various mobile phase pH conditions. (A) 0.1% formic acid (pH 2.8); 
(B) 0.1% acetic acid (pH 3.2); (C) 2 mM ammonium formate (pH 6.0); (D) 0.05% acetic acid with 5 mM ammonium acetate (pH 4.4); (E) 2 mM ammonium acetate 
(pH 6.7); (F) 10 mM ammonia (pH 9.8).www.frontiersin.org  August 2010  | Volume 1  | Article 10  |  11
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conditions were suitable for covering the whole set of compounds, 
stressing out that the testing of optimum conditions for each indi-
vidual compound leads always to clearly more high-quality data. 
Of the tested conditions, mobile phase with 0.05% acetic acid and 
5 mM ammonium acetate provided generally the best perform-
ance with easily ionizable compounds (acids and bases), whereas 
for neutral compounds the best overall performance was obtained 
with 2 mM ammonium formate as an aqueous mobile phase. The 
results also suggest that with the used injection solvent conditions, 
column chemistries, and positive ion mode LC–ESI–MS, poor 
chromatographic performance, rather than the poor ionization 
efficiency, may often be the limiting factor in analysis of basic com-
pounds. Noteworthy is also that two very commonly used aqueous 
mobile phases, i.e. 0.1% formic acid and 2 mM ammonium acetate, 
showed practically the poorest suitability for LC–ESI–MS analysis 
for all chemical classes (acids, neutrals, bases) among the different 
  aqueous mobile phases tested.
of compounds, as the performance with all of the 17 compounds 
fulfilled the set criteria for monitoring substrate depletion, and with 
14 of them the set criteria for metabolite profiling was fulfilled.
Within this class of compounds, problems in chromatography 
were not observed due to the compounds’ poor liquid state ioni-
zation properties. Instead, good retention behaviors and excellent 
peak shapes in all mobile phase pHs were obtained. An example of 
this is shown in Figure 6 as ion chromatograms of diuron, where the 
pH hardly has any effect to chromatography, and only decreasing 
effect to ionization in negative ion mode with 0.1% formic acid 
(trace A ESI−) and in positive ion mode with ammonium acetate 
in mobile phase (trace E ESI+).
conclusIons
Various mobile phase conditions were tested in developing meth-
ods for LC–ESI–TOF–MS analysis for metabolite profiling of 55 
structurally different compounds. No single or even two different 
FIgurE 5 | Positive ion mode LC–ESI–TOF–MS ion chromatograms for 
nicotine at various mobile phase pH conditions. (A) 0.1% formic acid (pH 
2.8); (B) 0.1% acetic acid (pH 3.2); (C) 2 mM ammonium formate (pH 6.0); 
(D) 0.05% acetic acid with 5 mM ammonium acetate (pH 4.4); (E) 2 mM 
ammonium acetate (pH 6.7); (F) 10 mM ammonia (pH 9.8). Peaks not integrated 
are not nicotine-related.Frontiers in Pharmacology  |  Drug Metabolism and Transport    August 2010  | Volume 1  | Article 10  |  12
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The conditions found here as most suitable for each individual 
test compound were used in metabolite profiling studies with rat and 
human liver microsomes and homogenates, providing high-quality 
data and enabling identification of high number of metabolites for 
most of the compounds (data will be published elsewhere).
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This in turn suggests that slightly acidic, but not too acidic, pH 
conditions would be the most optimum for generic LC–ESI–MS 
analysis of a large set of compounds. However, in this respect 
recent advances in liquid chromatographic techniques, utilizing 
sub-2 μm particles and usually referred with names such as ultra-
high performance liquid chromatography (UPLC) (Churchwell 
et al., 2005; Yu et al., 2006; Pedraglio et al., 2007) or rapid reso-
lution liquid chromatography (Yoshida and Majors, 2006), are 
to some extent improving the problem with poor peak shapes 
and may lead to a situation where the generic chromatogra-
phy works increasingly better and more emphasis can be put 
to ionization conditions. Still, this technical remedy does not 
however improve the situation with retention behavior but only 
with peak shapes.
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formate (pH 6.0); (D) 0.05% acetic acid with 5 mM ammonium acetate (pH 4.4); 
(E) 2 mM ammonium acetate (pH 6.7); (F) 10 mM ammonia (pH 9.8). Ionization 
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